Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(15):E2; doi:10.1093/jnci/djh242
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Trelle, S.
Right arrow Articles by Engert, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trelle, S.
Right arrow Articles by Engert, A.
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

ONLINE COMMENTARY

Biannual Report of the Cochrane Haematological Malignancies Group

Sven Trelle, Gail Higgins, Thilo Kober, Andreas Engert

Affiliations of authors: Cochrane Haematological Malignancies Group, Cologne, Germany (ST, GH, TK, AE); Department I of Internal Medicine, University of Cologne, Germany (ST, AE).

Correspondence to: Sven Trelle, MD, Department I of Internal Medicine, University of Cologne, Joseph-Stelzmann-Str. 9, 50924 Cologne, Germany (e-mail: sven.trelle@medizin.uni-koeln.de).

The first 150 words of the full text of this article appear below.


   INTRODUCTION
 
This first biannual report from the Cochrane Haematologiocal Malignancies Group (CHMG) highlights recently published systematic reviews as well as a selection of recently published and ongoing randomized controlled trials from the CHMG Trials Register (http://www.update-software.com/cochrane/). This register is being developed and maintained by the CHMG and currently contains references to approximately 3600 reports of randomized controlled trials that cover the scope of the group, including Hodgkin lymphoma, non-Hodgkin lymphoma, acute and chronic leukemias, aplastic anemia, and myelodysplastic syndromes.

We begin by highlighting recent (July through December 2003) systematic reviews and protocols. We then outline six recently published trials that were selected by the editorial base of the CHMG on the basis of clinical relevance, methodological rigor, and anticipated impact. 1) The HD8 trial, conducted by the German Hodgkin's Lymphoma Study Group, showed that involved field irradiation is as effective as but less toxic than extended field irradiation in . . . [Full Text of this Article]


   REVIEWS AND PROTOCOLS
 
CHMG Reviews

CHMG Protocols


   PUBLISHED TRIALS
 
Hodgkin Lymphoma

Indolent Non-Hodgkin Lymphoma

Aggressive Non-Hodgkin Lymphoma

Multiple Myeloma

Acute Myeloid Leukemia

Supportive Care

Other Published Trials of Potential Interest


   ONGOING TRIALS
 
Chronic Lymphocytic Leukemia

Acute Lymphocytic Leukemia

Chronic Myeloid Leukemia

Stem Cell Transplantation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

Second Biannual Report of the Cochrane Haematological Malignancies Group
Thilo Kober, Julia Bohlius, Sven Trelle, and Andreas Engert
J Natl Cancer Inst 2005 97: E1. [Extract] [Full Text]